Signify Health, which offers technology and analytics services to support value-based care arrangements, is expanding its in-home diagnostic and preventative services offering for Medicaid and Medicare Advantage plan members.
The program supports Signify’s In-Home Health Evaluation service, assisting with the detection, diagnosis and management of some of the leading causes of morbidity and mortality among Medicare beneficiaries, like peripheral arterial disease, chronic obstructive pulmonary disease, chronic kidney disease and diabetes.
The newest offering is spirometry testing to evaluate patients for COPD, which Signify said it began providing in some areas this year.
“Early diagnosis and management of chronic conditions are critical to achieving better health outcomes and reducing the total cost of care,” Dr. Marc Rothman, chief medical officer of Signify Health, said in a statement. “At Signify, we are performing diagnostic tests in the home to reduce barriers to timely diagnosis and treatment decisions by individuals and their physicians.”
THE LARGER TREND
CVS Health recently signed a definitive agreement to acquire publicly-traded Signify Health for $30.50 per share in cash, representing an approximately $8 billion total transaction value. The retail giant beat out Amazon and UnitedHealth Group in the bid.
The agreement comes months after Signify announced its acquisition of Caravan Health, a startup focused on helping providers transition into accountable care organizations, which partners with over 170 providers participating in accountable care organizations (ACOs) serving Medicare beneficiaries.
“This acquisition will enhance our connection to consumers in the home and enables providers to better address patient needs as we execute our vision to redefine the healthcare experience. In addition, this combination will strengthen our ability to expand and develop new product offerings in a multi-payer approach,” CVS Health president and CEO Karen S. Lynch said in a statement when the deal was announced.